Dr. Robert Spiegel Joins Advisory Board at BioPontis Alliance
Announcing important addition to luminary board of advisors.
- (1888PressRelease) May 08, 2012 - BioPontis Alliance is continuing to build their circle of expertise in translational research and early stage biopharmaceutical investments with their announcement today that Dr. Robert Spiegel is joining their Advisory panel.
Dr. Spiegel brings deep executive leadership experience with more than 26 years of senior VP executive roles at Schering-Plough in clinical development, culminating in a decade as Chief Medical Officer.
Prior to his global responsibilities in clinical development and well aligned to BioPontis' therapeutic focus, Dr. Spiegel had previously led cancer and anti-infectives drug development as Director for Oncology Clinical research at Schering, as well as Senior Director for Anti-Infectives.
"We are truly honored to have Robert Spiegel join the BioPontis Advisory board. His recognition and support of our novel approach to traversing the Valley of Death to reinvigorate the pharmaceutical sector with quality pre-clinical stage compounds is an important affirmation that the industry can be - and must be - restructured.", says BioPontis Alliance's founder, Richard Basile.
" Dr. Spiegel brings the required perspective of the clinical development hurdles, but equally importantly, a deep knowledge of how the beginning of the pipeline can make enormous differences in the value of new medicines emerging from the entire industry."
Dr. Spiegel earned his B.A. from Yale University and M.D. from the University of Pennsylvania. He has published over 70 scientific papers and serves on the Board of Directors of a number of biotech companies.